Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

843 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines.
van Montfoort N, Borst L, Korrer MJ, Sluijter M, Marijt KA, Santegoets SJ, van Ham VJ, Ehsan I, Charoentong P, André P, Wagtmann N, Welters MJP, Kim YJ, Piersma SJ, van der Burg SH, van Hall T. van Montfoort N, et al. Among authors: andre p. Cell. 2018 Dec 13;175(7):1744-1755.e15. doi: 10.1016/j.cell.2018.10.028. Epub 2018 Nov 29. Cell. 2018. PMID: 30503208 Free PMC article.
Monalizumab: inhibiting the novel immune checkpoint NKG2A.
van Hall T, André P, Horowitz A, Ruan DF, Borst L, Zerbib R, Narni-Mancinelli E, van der Burg SH, Vivier E. van Hall T, et al. Among authors: andre p. J Immunother Cancer. 2019 Oct 17;7(1):263. doi: 10.1186/s40425-019-0761-3. J Immunother Cancer. 2019. PMID: 31623687 Free PMC article. Review.
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.
André P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Bléry M, Bonnafous C, Gauthier L, Morel A, Rossi B, Remark R, Breso V, Bonnet E, Habif G, Guia S, Lalanne AI, Hoffmann C, Lantz O, Fayette J, Boyer-Chammard A, Zerbib R, Dodion P, Ghadially H, Jure-Kunkel M, Morel Y, Herbst R, Narni-Mancinelli E, Cohen RB, Vivier E. André P, et al. Cell. 2018 Dec 13;175(7):1731-1743.e13. doi: 10.1016/j.cell.2018.10.014. Epub 2018 Nov 29. Cell. 2018. PMID: 30503213 Free PMC article. Review.
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.
Romagné F, André P, Spee P, Zahn S, Anfossi N, Gauthier L, Capanni M, Ruggeri L, Benson DM Jr, Blaser BW, Della Chiesa M, Moretta A, Vivier E, Caligiuri MA, Velardi A, Wagtmann N. Romagné F, et al. Among authors: andre p. Blood. 2009 Sep 24;114(13):2667-77. doi: 10.1182/blood-2009-02-206532. Epub 2009 Jun 24. Blood. 2009. PMID: 19553639 Free PMC article.
Human NK cell education by inhibitory receptors for MHC class I.
Anfossi N, André P, Guia S, Falk CS, Roetynck S, Stewart CA, Breso V, Frassati C, Reviron D, Middleton D, Romagné F, Ugolini S, Vivier E. Anfossi N, et al. Among authors: andre p. Immunity. 2006 Aug;25(2):331-42. doi: 10.1016/j.immuni.2006.06.013. Epub 2006 Aug 10. Immunity. 2006. PMID: 16901727 Free article.
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.
Kohrt HE, Thielens A, Marabelle A, Sagiv-Barfi I, Sola C, Chanuc F, Fuseri N, Bonnafous C, Czerwinski D, Rajapaksa A, Waller E, Ugolini S, Vivier E, Romagné F, Levy R, Bléry M, André P. Kohrt HE, et al. Among authors: andre p. Blood. 2014 Jan 30;123(5):678-86. doi: 10.1182/blood-2013-08-519199. Epub 2013 Dec 10. Blood. 2014. PMID: 24326534 Free PMC article.
843 results